Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
Readen Holding Corporation (OTC Pink: RHCO) is a listed venture capital corporation with over 30 years of activity. The Company has a long history of engaging in the retail trade. More recently, it has been active in the Fintech, Online Payment and E-commerce industries, a vast potential growth sector es-North America. RHCO has subsidiaries and liaison offices in Europe, Asia and New Zealand.
Investors tend to eschew OTC pink stocks, but the adage everyone has to start somewhere is appropriate in Raeden’s case. And in many instances, the companies represent value in plain sight.
Should you want an accurate world comparison, many core people at Readen cut their teeth at Groupon.
An example of the approach from the latest PR:
OkePartners are the individuals, companies or charities who can share their invitation code with anyone to become OkeMembers. OkeMembers can enjoy great discounts offered by OkeMerchants. For all the spending of OkeMembers at OkeMerchants through OkeApp, the corresponding OkePartner would receive a commission of up to 5% of the discounted amount.
The Company also announced today that since the soft launch of OkeApp early this year, it had recruited more than 500 OkePartners.
As well as two recent personnel acquisitions; Siegfried Yu as the Chief Financial Officer of the Company and Ernest Kwan as the General Manager of OkeApp (www.okepartners.com).
The OKE App has 131k merchants total, 568 partners and over 1.8 million members: Virtually every type of good is available, from retail to clothing to travel to food.
Readon’s strength is acquiring distressed assets, selling off the weak parts, and growing the best assets. The free App is available in all the usual places.
The Company is aggressively pursuing an uplisting to the OTCQB. It hopes to conclude this tear.
Richard Klitsie, CEO of RHCO, stated, “RHCO has started the year of 2022 very well, and we are thrilled to announce the completion of its quarterly filing. We are riding on the momentum of OkeApp and Readies, and both are performing well beyond our expectations.”
RHCO reported an increase in Revenue of 634.42% compared to the quarter ending December 2021, which is also a year-over-year increase of 161.39%. After two previous quarters of a minor loss, the Company has recorded a nominal profit, and its Net Assets saw a rise of 1.99% compared to last year’s end.
Here is a link to what can only be described as historically impressive quarterly results. While the concept is simple, there is no predicting what businesses will be added to the mix. Given the provenance of the executives, the risk/reward scale seems to tilt to the latter.
Readen is an aggressive trader with a 52-week range of USD$0.02 to USD0.21. Not a bad run for a pinkie.
Lots more to this one. Lots.
Financials
Valuation
Market Capitalization16.457M
Enterprise Value (MRQ)22.03M
Enterprise Value/EBITDA (TTM)—
Total Shares Outstanding (MRQ)324.277M
Number of Employees—
Number of Shareholders765
Price to Earnings Ratio (TTM)—
Price to Revenue Ratio (TTM)—
Price to Book (FY)1.0935
Price to Sales (FY)8.2338
Balance Sheet
Quick Ratio (MRQ)0.3518
Current Ratio (MRQ)0.3752
Debt to Equity Ratio (MRQ)0.4630
Net Debt (MRQ)7.078M
Total Debt (MRQ)7.115M
Total Assets (MRQ)28.27M
Operating Metrics
Return on Assets (TTM)—
Return on Equity (TTM)—
Return on Invested Capital (TTM)—
Revenue per Employee (TTM)—
Margins
Net Margin (TTM)—
Gross Margin (TTM)—
Operating Margin (TTM)—
Pretax Margin (TTM)—
Income Statement
Basic EPS (FY)0.0057
Basic EPS (TTM)—
EPS Diluted (FY)0.0057
Net Income (FY)1.853M
EBITDA (TTM)—
Gross Profit (MRQ)357.588K
Gross Profit (FY)1.335M
Last Year’s Revenue (FY)1.999M
Total Revenue (FY)1.999M
©2024 10xAlerts